Ontario Teachers Pension Plan Board Has $4.24 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Ontario Teachers Pension Plan Board decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 6.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,703 shares of the medical research company’s stock after selling 1,076 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Amgen were worth $4,235,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WealthPlan Investment Management LLC raised its position in shares of Amgen by 82.6% in the third quarter. WealthPlan Investment Management LLC now owns 840 shares of the medical research company’s stock valued at $226,000 after purchasing an additional 380 shares during the period. Advisor OS LLC grew its stake in shares of Amgen by 18.5% in the third quarter. Advisor OS LLC now owns 1,234 shares of the medical research company’s stock valued at $332,000 after acquiring an additional 193 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Amgen by 2.5% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 5,001 shares of the medical research company’s stock valued at $1,344,000 after acquiring an additional 123 shares in the last quarter. Main Street Financial Solutions LLC grew its stake in shares of Amgen by 4.7% in the third quarter. Main Street Financial Solutions LLC now owns 2,537 shares of the medical research company’s stock valued at $682,000 after acquiring an additional 113 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Amgen in the third quarter valued at about $288,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 1.7 %

NASDAQ AMGN traded down $5.44 during trading hours on Wednesday, reaching $309.41. The company’s stock had a trading volume of 2,842,511 shares, compared to its average volume of 2,842,832. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The firm has a fifty day simple moving average of $282.91 and a 200-day simple moving average of $284.96. The stock has a market cap of $165.98 billion, a P/E ratio of 44.78, a P/E/G ratio of 2.83 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.76 by $0.20. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company’s revenue was up 22.0% compared to the same quarter last year. During the same quarter last year, the business earned $3.98 EPS. Equities analysts forecast that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.91%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is currently 128.57%.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Mizuho upped their price target on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Royal Bank of Canada reduced their price objective on shares of Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. Truist Financial reiterated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Finally, UBS Group increased their price objective on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $305.65.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.69% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.